KEYTRUDA
The latest news about KEYTRUDA: headlines, AI summaries and the full story from every source.
- Dutch Court Bans Merck's Injectable Version of Keytruda in Certain European Markets
- Moderna Stock Surges Over 550% Amid Cancer Vaccine Hype; Is It Too Late to Buy?
- Bank of America Maintains Buy Rating on Merck Following Private Meeting with Chief Medical Officer
- Moderna Reaches New High Ahead of Upcoming Pipeline Updates
- Merck Receives Japanese Approval for Subcutaneous Version of Keytruda
- Moderna and Merck Announce Positive Phase 3 Trial Results for Personalized Cancer Vaccine
- Moderna Stock Surges on Positive Phase 3 Melanoma Trial Results
- Moderna and Merck's Melanoma Therapy Meets Primary Goal in Phase 3 Trial
- Merck Expands Kidney Cancer Treatment with FDA Approval of KEYTRUDA and WELIREG Combination
- Merck's Lung Cancer Combo Outperforms Keytruda in Late-Stage Trial
- Merck Reports Quarterly Loss Amid Cidara Charge, Sales Rise 5%
- Merck Exceeds Q1 Earnings Estimates with Strong Oncology Sales
- Merck Exceeds Quarterly Estimates with Keytruda and New Products, Adjusts 2026 Guidance